No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PHIO Phio Pharmaceuticals
- 4.5000
- +0.1310+3.00%
Close Jul 19 16:00 ET
- 4.4000
- -0.1000-2.22%
Pre 08:00 ET
2.30MMarket Cap-198P/E (TTM)
4.6800High4.0000Low42.20KVolume4.2800Open4.3690Pre Close185.52KTurnover8.33%Turnover RatioLossP/E (Static)510.19KShares29.070052wk High0.41P/B2.28MFloat Cap3.900052wk Low--Dividend TTM506.32KShs Float3118.4994Historical High--Div YieldTTM15.56%Amplitude3.9000Historical Low4.3960Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Marlborough, Massachusetts–(Newsfile Corp. – July 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Phio Pharmaceuticals Corp -Deal Afforded Triton Opportunity to Purchase up to 18.8% of Co’s Common Stock
Express News | Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds, Which Afforded Triton Opportunity To Purchase Up To 18.8% Of Co.'s Common Stock
Express News | Phio Pharmaceuticals Corp - Terminates Share Purchase Agreement With Triton
Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology
Comments
$Phio Pharmaceuticals(PHIO.US$ Low float, keeping an eye on this.
$Phio Pharmaceuticals(PHIO.US$
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Phio Pharmaceuticals (NASDAQ: PHIO) announced the inclusion of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology as a clinical trial site for its Phase 1b study of PH-762, bringing the total to five participating sites. This trial involves adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma and aims to...
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Phio Pharmaceuticals (NASDAQ: PHIO) announced the inclusion of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology as a clinical trial site for its Phase 1b study of PH-762, bringing the total to five participating sites. This trial involves adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma and aims to...
$Phio Pharmaceuticals(PHIO.US$ Phio Pharmaceuticals Corp - Has Approved a Reverse Stock Split of Its Shares of Common Stock at a Ratio of 1-for-9! Will become effective July 5
$Phio Pharmaceuticals(PHIO.US$ Phio Pharmaceuticals Announces Positive Recommendation From Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
newsfile· 5 mins ago
Intratumoral PH-762 has encouraging safety profile in the initial cohort
Escalation to proceed to next dose concentration
newsfile· 5 mins ago
Intratumoral PH-762 has encouraging safety profile in the initial cohort
Escalation to proceed to next dose concentration
$Phio Pharmaceuticals(PHIO.US$ Phio Pharmaceuticals Corp Files for Mixed Shelf of up to $100 Mln - SEC Filing
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg